---
title: Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
date: '2024-09-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39268857/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240913201224&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Adjuvant therapy with durvalumab led to significantly longer
  overall survival and progression-free survival than placebo among patients with
  limited-stage small-cell lung cancer. (Funded by AstraZeneca; ADRIATIC ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Adjuvant therapy with durvalumab led to significantly longer overall survival and progression-free survival than placebo among patients with limited-stage small-cell lung cancer. (Funded by AstraZeneca; ADRIATIC ClinicalTrials.gov number, ...